Archive for the 'Lawrence Broxmeyer' Category

CWD Tuberculosis Found in Spongiform Disease Formerly Attributed to Prions: Its Implication towards Mad Cow Disease, Scrapie and Alzheimer’s

May 9, 2017


Journal of MPE Molecular Pathological Epidemiology 2017 Vol. 3 No. 3: 3

Lysenko AP PhD,
Broxmeyer L MD,
Vlasenko VV PhD,
Krasochko PA PhD,
Lemish AP and
Krasnikova EL


The TSE’S or transmissible spongiform encephalopathies, include bovine spongiform encephalopathy (also called BSE or “mad cow disease”), Creutzfeldt– Jakob disease (CJD) in humans, and “scrapie” in sheep or goats (caprine spongiform encephalopathy).  They remain a mystery, their cause still hotly debated. Current mad cow diagnosis lies solely in the detection of late appearing “prions”, an acronym for hypothesized, geneless, misfolded proteins, somehow claimed to cause the disease. Yet laboratory preparations of prions contain other things, which could include unidentified bacteria or viruses. And the only real evidence that prion originator Stanley Prusiner had in his original paper that the disease agent behind “Scrapie” in sheep and goats was devoid of DNA or RNA– was based upon the fact that he couldn’t find any. Furthermore, the rigors of prion purification alone, might, in and of themselves, have killed any causative microorganism and Heino Dringer, who did pioneer work on their nature, candidly predicts “it will turn out that the prion concept is wrong.” Roels and Walravens as well as Hartly traced Mad Cow to Mycobacterium bovis. Moreover, epidemiologic maps of the origins and peak incidence of Mad Cow in the UK, suggestively match those of England’s areas of highest bovine tuberculosis, the Southwest. The neurotaxic potential of bovine tuberculosis has for some time been well known. By 1911 Alois Alzheimer called attention to “a characteristic condition of the cortical tissue which Fischer referred to as ‘spongy cortical wasting” in Alzheimer’s disease (AD). But behind AD, Fischer suspected a microbe called Streptothrix which was constantly being mistaken and confused for tuberculosis. Our present investigation of the TSEs clearly shows cell-wall-deficient (CWD) tubercular mycobacteria present, verified by molecular analysis, ELISA, PCR and microscopy to cause spongiform encephalopathy.

Keywords: Prions; Scrapie; The Spongiform Encephalopathies; Alzheimer’s disease; The etiology of Alzheimer’s Disease; Mycobacterium tuberculosis Complex

Received: April 05, 2017; Accepted: April 27, 2017; Published: April 29, 2017



1   Curto M, Reali C, Palmieri G, Scintu F, Schivo ML, et al. (2004) Inhibition of Cytokines Expression in Human Microglia Infected with Virulent  and  Nonvirulent  Mycobacteria.  Neurochem  Internat  44: 381-392.

2    Broxmeyer  L,  Sosnowska  D,  Miltner  E,  Chacón  O,  Wagner  D,  et al. (2002) Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis 186: 1155-1160.

3    Randall PJ, Hsu NJ, Lang D, Cooper S, Sebesho B, et al. (2014) Neurons are host cells for Mycobacterium tuberculosis. Infect Immun 82: 1880-1890.

4    Manuelidis  EE,  Manuelidis  L  (1989)  Suggested  Links  Between Different Types of Dementias: Creutzfeldt-Jakob disease, Alzheimer disease, and Retroviral CNS Infections. Alzheimer Dis Assoc Disord 3: 100-109.

5    Stockman S (1911) The habits of British ticks found on sheep and cattle. J Comp Pathol 24: 229-37.

6    Fischer O (1911) The spongious loss of the bones, a special process of destruction of the cerebral cortex. Z ges Neurol Psychiat 7: 1-33.

7   Babes V, Levaditi C (1897) On the Actinomycotic Shape of the Tuberculosis Bacilli (Sur la Forme Actinomycosique du Bacilli de la Tuberculosis). Arch of Med Exp et D’anat 9: 1041-1048.

8    Dunkin GW (1936) Paratuberculosis of Cattle and Sheep. Section of Comparative Medicine. Proc R Soc Med 30: 83-90

9    Chauveau A: Transmission of virulent diseases by the ingestion of virulent principles in the digestive tract. Gaz de Paris: p 45.

10  Klebs E (1870) On the history of tuberculosis. Virchows Arch F path Anat :p 291

11  Gerlach  AC  (1870)  On  the  inoculability  of  tuberculosis  and  the perilla, and on the transferability of the latter by feeding. Virchows Arch F path Anat 11: 297.

12  Pfeiffer DU (1994) The role of a wildlife reservoir in the epidemiology of bovine tuberculosis. Massey University, Dept of Veterinary Clinical Sciences, New Zealand.

13 Bourne J, Donnelly C (2001) An epidemiological investigation into bovine tuberculosis third report of the Independent Scientific Group on Cattle TB.

14  Francis  J  (1947)  Bovine  Tuberculosis:  Including  a  Contrast  with Human Tuberculosis. Staples Press Limited, London: p 220.

15  Taubes G (1986) The game of the name is fame. But is it science? Discover 7: 28-52.

16 Hadlow WJ, Prusiner SB, Kennedy RC, Race RE (1980) Brain tissue from persons dying of Creutzfeldt-Jacob disease causes scrapie-like encephalopathy in goats. Ann Neurol 8: 628-631.

17  Griffith JS (1967) Self-replication and scrapie. Nature 215: 1043-4.

18  Prusiner SB (1995) The  prion  diseases. Sci Am 272: 48-51.

19  Pethe K, Bifani P, Drobecq H, Sergheraert C, Debrie AS, et al. (2002) Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc Natl Acad Sci USA 2002 99: 10759-10764.

20  Tsubuki S, Takako Y (2003) Dutch,    Flemish,    Italian    and Arctic mutations of App and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361: 1957-1958.

21  Lasmézas  CI,  Deslys  JP  (1997)  Transmission  of  the  BSE  agent to mice in the absence of detectable abnormal prion protein. Science 275: 402-405.

22  Baker  CA, Martin D, Manuelidis L (2002) Microglia from  Creutzfeld– Jakob disease-infected brains are   infectious and   show specific mRNA activation profiles. J Virol 76: 10905-10915.

23  Botsios S, Manuelidis L (2016) CJD and Scrapie Require Agent- Associated  Nucleic  Acids  for  Infection.  J  Cell  Biochem  117: 1947-1958.

24  Abalos P, Retamal P (2004) Tuberculosis: a re-emerging zoonosis? Rev Sci Tech 23: 583-94.

25  O’Reilly LM, Daborn CJ (1995) The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tuber Lung Dis 76: 1-46.

26  Grange JM (2001) Mycobacterium bovis infection in human beings. Tuberculosis 81: 71-77

27  Mattman LH (2001) Cell Wall Deficient Forms: Stealth Pathogens.CRC Press 3 (416).

28  Xalabarder C (1958) Electron microscopy of tubercle bacilli. Excerpta Medica. Sec XV Chest Dis 11: 467-473.

29  Xalabarder C (1963) The Nature of So-Called Atypical Mycobacteria. Neumol Cir Torax 24: 259-74.

30  Csillag A (1964) The mycococcus form of mycobacteria. Journ of Gen Microbio 34: 341-352

31  Shleeva  MO,  Salina  EG,  Kaprel’iants  AS  (2010)  Dormant  form  of Mycobacterium tuberculosis. Mikrobiologiia 79: 3-15

32  Zhang Y, Yang Y, Woods A, Cotter RJ, Sun Z (2001) Resuscitation of dormant Mycobacterium tuberculosis by phospholipids or specific peptides. Biochem Biophys Res Commun 284: 542-547.

33 Marcova N, Slavchev G, Michailova L (2012) Unique biological properties of Mycobacterium tuberculosis L-form variants: impact for survival under stress. Int. Microbiol 15: 61-68.

34  Shleeva MO, Mukamolova GV, Telkov MV, Berezinskaia TL, Syroeshkin AV et al. (2003) Formation of nonculturable Mycobacterium tuberculosis and their regeneration. Mikrobiologiia 72: 76-83.

35  Prusiner SB (2014) Madness and Memory: The Discovery of Prions – A New Biologic Principle of Disease. Yale University Press.

36  Hass G, Huntington R (1943) Amyloid. III The properties of amyloid deposits occurring in several species under diverse conditions. Arch Pathol 35: 226.

37 Schwartz P (1972) Amyloid degeneration and tuberculosis in the aged. Gerontologia 18: 321-362.

38 Delgado WA (1997) Amyloid deposits in labial salivary glands identified by electron microscopy. J Oral Pathol Med 26: 51-52.

39  de Beer FC, Nel AE (1984) Serum amyloid A protein and C-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis. Thorax 39: 196–200.

40  Tomiyama T, Satoshi A (1994) Rifampicin prevents the aggregation and neurotoxicity of amyloid B protein in vitro. Biochem Biophys Res Commun 204: 76-83.

41  Chauhan A, Madiraju MV, Fol M, Lofton H, Maloney E, et al. (2006) Mycobacterium  tuberculosis  Cells  Growing  in  Macrophages  Are Filamentous and Deficient in FtsZ Rings. J. Bacteriol 188: 1856-1865.

42 Markova N, Michailova L, Kussovski V, Jourdanova M (2008) Formation of Persisting Cell Wall Deficient Forms of Mycobacterium bovis BCG during Interaction with Peritoneal Macrophages in Guinea Pigs. Electronic Journal of Biology 4: 1-10

43 Thacore H, Willett HP (1966) The formation of spheroplasts of Mycobacterium tuberculosis in tissue culture cells. Am Rev Respir Dis 93: 786-796.

44 Lysenko AP, Vlasenko AP, Broxmeyer L (2014) Phenomenon of variability of mycobacteria and its use for detection of a tuberculosis infection.

45 Lysenko AP, Vlasenko VV, Broxmeyer L, Lemish AP, Novik TP, et al. (2014) The tuberculin skin test: how safe is safe?  The tuberculins contain unknown forms capable of reverting to cell-wall-deficient mycobacteria. Clinical and Experimental Medical Sciences 2: 55-73.

46  Lysenko  AP,  Broxmeyer  L,  Vlasenko  V,  Krasochko  PA,  Lemish  AP, et al. (2016) Further evidence for Cancer as Cell-wall-deficient Mycobacterial Disease. J Mol Pathol Epidemiol 1: 1-12.

47  Lysenko AP, Vlasenko VV, Lemish AP (2014) Detection of mycobacteria in tis- sues by means of the differentiating  immunoperoxidase staining. Tuberculos i bolezni legkhih. 10: 55-58.

48  Harry EJ (2001) Bacterial cell division: regulating Z-ring formation. Mol Microbiol 40: 795-803.

49  Errington J, Daniel RA, Scheffers DJ (2003) Cytokinesis in bacteria. Microbio Mol Biol Rev 67: 52-65.

50  Xalabarder C (1970) L-forms of chronic mycobacteria and nephritis. Publ Inst Antituberc(Barcelona) Supple 7:7-83.

51 Seidel B, Thomzig A, Buschmann A, Groschup MH, Peters R, et al. (2007) Scrapie agent (strain 263K) can transmit disease via the oral route after persistence in soil over years. PLoS One 2: e435.

52  Ghodbane R, Mba Medie F, Lepidi H, Nappez C, Drancourt M (2014) Long-term survival of tuberculosis complex mycobacteria in soil. Microbiology 160: 496-501.

53  Insanov AB, Gadzhiev FS (1996) Comparative Analysis of the Results of Spinal Fluid Microbiological Study in Children and Adults Who Suffered from Tuberculous Meningitis. Probl tuberk. 5: 25–28.

54  Slavchev  G,  Michailova  L,  Markova  N  (2013)  Stress-induced L-forms of M. bovis: challenge to survivability. New Microbiologica 36: 157-166.

55  Calmette A, Valtis J, Lacomme A (1928) New experimental research on tuberculous ultravirus. CR Acad Sci 186: 1778-1781.

56  Xiao X, Miravalle L, Yuan J, McGeehan J, Dong Z, et al. (2009) Failure to Detect the Presence of Prions in the Uterine and Gestational Tissues from a Gravida with Creutzfeldt – Jakob disease. Am J Pathol 174: 1602-1608.

57  Brieger EM (1949) The Host Parasite Relationship in Tuberculous Infection. Tubercle 30: 242-253.

58 Brieger EM, Glauert AM (1952) A Phase-Contrast Study of Reproduction in Mycelial Strains of Avian Tubercle Bacilli. J Gen Microbiol 7: 287-294.

59  Prusiner SB (2004) Development of the Prion Concept. Prion Biology and Diseases, Cold Spring Harbor Laboratory Press: pp 89-141.

60  Pattison IH (1988) Fifty years with scrapie: a personal reminiscence. Vet Rec 123: 661-666.

61  Pattison IH, Jones KM (1967) The possible nature of the transmissible agent of scrapie. Vet Rec 80: 7.

62  Gerston KF, Blumberg L, Tshabalala VA, Murray J (2004) Viability of mycobacteria in formalin-fixed lungs. Hum pathol 35: 571-575.

63  Vinnie DS, Mary R (2002) Does formaldehyde kill Myco tuberculosis? Tech Bull Histopath 2: 37-38.

64  Alzheimer A, Forstl H, Levy R (1991) On Certain Peculiar Diseases of Old Age. History of Psychiatry 2: 71-101.

65  Goedert M (2015) Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aß, tau and α-synuclein. Science 349: 1255555.

66 Schwab C, Hosokawa M, McGeer PL (2004) Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188: 52-64

67 Mawanda F, Wallace R (2013) Can infections cause Alzheimer’s disease? Epidemiol Rev 35: 161-80.

68  Alteri CJ, Xicahténcati-Cortes J, Hess S, Caballero-Olin G, Girón JA,et al. (2007) Mycobacterium Tuberculosis Produces Pili during Human Infection. Proc Natl Acad Sci USA 104: 5145-5150.

69 Jordal PB, Dueholm MS, Larsen P, Petersen SV, Enghild JJ, et al. (2009)  Widespread  abundance  of  functional  bacterial  amyloid in mycolata and other gram-positive bacteria. Appl Environ Microbiol 75: 4101-4110.


Killing of Mycobacterium avium and Mycobacterium tuberculosis by a Mycobacteriophage Delivered by a Nonvirulent Mycobacterium: A Model for Phage Therapy of Intracellular Bacterial Pathogens

January 12, 2017
Lawrence Broxmeyer, Danuta Sosnowska, Elizabeth Miltner, Ofelia Chacon, Dirk Wagner, Jeffery McGarvey, Raul G. Barletta, and Luiz E. Bermudez

Killing of Mycobacterium avium and Mycobacterium tuberculosis by a Mycobacteriophage

The Journal of Infectious Diseases


Mycobacterium avium causes disseminated infection in patients with acquired immune deficieny syndrome. Mycobacterium tuberculosis is a pathogen associated with the deaths of millions of people worldwide annually. Effective therapeutic regimens exist that are limited by the emergence of drug resistance and the inability of antibiotics to kill dormant organisms. The present study describes a system using Mycobacterium smegmatis, an avirulent mycobacterium, to deliver the lytic phage TM4 where both M. avium and M. tuberculosis reside within macrophages. These results showed that treatment of M. avium–infected, as well as M. tuberculosis –infected, RAW 264.7 macrophages, with M. smegmatis transiently infected with TM4, resulted in a significant time and titer  dependent reduction in the number of viable intracellular bacilli. In addition, the M. smegmatis vacuole harboring TM4 fuses with the M. avium vacuole in macrophages. These results suggest a potentially novel concept to kill intracellular pathogenic bacteria and warrant future development.

1. Bloom B. Tuberculosis: pathogenesis, protection and control. Washington,DC: American Society for Microbiology Press, 1995.
2. Surveillance TWIGP. Anti-tuberculosis drug resistance in the world. Geneva:World Health Organization Global Tuberculosis Programme, 1997.
3. Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clin Microbiol Rev 1993; 6:266–310.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60.
5. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus–associated opportunistic infections in the United
States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000 ; 30(Suppl 1):S5–14.
6. Falkinham JO 3rd. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996; 9:177–215.
7. Guthertz LS, Damsker B, Bottone EJ, Ford EG, Midura TF, Janda JM. Mycobacterium avium and Mycobacterium intracellulare infections in patients with and without AIDS. J Infect Dis 1989; 160:1037–41.
8. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996; 40:1759–67.
9. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:1332–8.
10. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121:905–11.
11. Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium–intracellulare complex infection in patients with AIDS. Lancet 1991; 338:1107–9.
12. Bermudez LE, Kolonoski P, Young LS. Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice. Antimicrob Agents Chemother 1996; 40:1033–5.
13. Dube MP, Sattler FR, Torriani FJ, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J Infect Dis 1997; 176:1225–32.
14. Holzman D. Phage as antibacterial tool. Genetic Engineering News 1998; 18:11–16.
15. Ford ME, Stenstrom C, Hendrix RW, Hatfull GF. Mycobacteriophage TM4: genome structure and gene expression. Tuber Lung Dis 1998; 79:63–73.
16. Foley-Thomas EM, Whipple DL, Bermudez LE, Barletta RG. Phage infection,transfection and transformation of Mycobacterium avium complex and Mycobacterium paratuberculosis. Microbiology 1995; 141:1173–81.
17. Bermudez LE, Parker A, Goodman JR. Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor–independent pathway. Infect Immun 1997; 65:1916–25.
18. Jacobs WR Jr, Kalpana GV, Cirillo JD, et al. Genetic systems for mycobacteria. Methods Enzymol 1991; 204:537–55.
19. Black CM, Bermudez LE, Young LS, Remington JS. Coinfection of macrophages modulates interferon gamma and tumor necrosis factor–induced activation against intracellular pathogens. J Exp Med 1990; 172:977–80.
20. Hafner R, Inderlied CB, Peterson DM, et al. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis 1999; 180:438–47.
21. Sula L, Sulova J, Stolcpartova M. Therapy of experimental tuberculosis in guinea pigs with mycobacterial phages DS-6A, GR-21 T, My-327. Czech Med 1981; 4:209–14.
22. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35:462–70.
23. Bermudez LE, Young LS. New drugs for the therapy of mycobacterial infections. Curr Opinion Infect Dis 1995; 8:428–38.
24. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994; 263:678–81.
25. Clemens DL, Horwitz MA. Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J Exp Med 1995
; 181:257–70.
26. de Chastellier C, Lang T, Thilo L. Phagocytic processing of the macrophage endoparasite, Mycobacterium avium, in comparison to phagosomes which contain Bacillus subtilis or latex beads. Eur J Cell Biol 1995; 68:167–82.
27. Gomes MS, Paul S, Moreira AL, Appelberg R, Rabinovitch M, Kaplan G. Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages. Infect Immun 1999; 67:3199–206.


November 20, 2014

 Dr. Lawrence Broxmeyer, MD


The CDC has quietly lowered its “critical temperature” protocols for detecting a fever ‘characteristic’ for Ebola after one health care worker slid by with a low-grade fever ― yet tested Ebola positive ― So……
“We changed to 100.4 after the first nurse presented to hospital with symptoms of disease and her temp was not the 101.5 that Ebola patients usually present when they are having vomiting diarrhea, etcetera,” CDC spokesman Thomas Skinner told the Daily Caller.
Etcetera. Etcetera. What Skinner meant is their Ebola temperature criteria has been changed to a temperature of 100.4ºF or above.
Anyway 100.4° (or above) sounds like a nice round number. So let’s examine it.
On the National Health Service’s website, put up by the UK government, the now magically designated temperature of100.4ºF or above also appears ― but not for Ebola. They are describing temperatures characteristic for tuberculosis. (

And, it might be added, temperatures characteristic for a dozen-and-a-half other illnesses.
So much for the use of temperature as an Ebola criteria.

Subsequently, by October the 20th ― World Health Organization (WHO) claimed Nigeria, which used to have the highest ‘Ebola’ death rate of any country in the world (See: – “Ebola-free” Great, but does that they can say the same about the Ebola-like symptoms originating from the African strains of tuberculosis ― namely Mycobacterium tuberculosis and Mycobacterium africanum ― still raging over there? Will they next proclaim West Africa “Tuberculosis-free?”

Extrapulmonary (outside of the lungs) tuberculosis is the most frequent cause of a prolonged Fever of Unknown Origin (FUO) and has been for a long, long time.1,2
And in patients returning from areas where tuberculosis and malaria are
Common ― such as Africa ― the index of suspicion for these diseases should be elevated.
The current question………………… is it?

1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Casademont J. Harrison’s Principles of Internal Medicine. 16th Edition. 2004. McGraw-Hill Professional Publishing. 2680 pp
2. Roth AR, Basello GM. Approach to the adult patient with fever of unknown origin.Am Fam Physician. 2003 Dec 1;68(11):2223-8.

See also:  Ebola & African TB – An Interview With Dr. Lawrence Broxmeyer, MD Part 1  Jeff Rense Dr. Lawrence Broxmeyer, MD 11-6-14
Ebola & African TB – An Interview With Dr. Lawrence Broxmeyer, MD Part 2
Is The Ebola Virus Real? From Dr. Lawrence Broxmeyer, M.D. © U.S. Library of Congress All rights reserved 11-9-14

Vitamin C and Its Unauthorized High-Dose Use for Ebola

November 4, 2014

Dr. Lawrence Broxmeyer, MD


© U.S. Library of Congress. All rights reserved. November 1, 2014



Vitamin C is at present untested and unapproved for treatment of the current Ebola virus outbreak. Yet its mention by many, as in past outbreaks and epidemics, is predictably being brought up. A bleeding tendency in both severe lack of Vitamin C and in Ebola is cited. Vitamin C, in moderation, is essential to our good health ― the key word being moderation. Curiously, in the current atmosphere, many believe that if Vitamin C is working to relieve a patient’s symptoms, then it must be a “virus” that it is working against ― despite repeated assurance in the literature that a “viral-like” illness does not mean a viral-caused illness. Perhaps some Vitamin C history is in order.

In 1976, two-time Nobel laureate Linus Pauling, tempered by his 1971 publication Vitamin C and the Common Cold1, published a similar sounding title ― Vitamin C. the Common Cold, and the Flu.2 And, at the same time, Pauling tossed his hat into the cancer arena by co-authoring a study regarding Vitamin C and cancer. Entitled Supplemental Ascorbate (Vitamin C) in the Supportive Treatment of Cancer, it was written with a medical doctor (Pauling was a PhD) from Scotland named Ewan Cameron.3 In the study 100 “terminal” cancer patients were treated with mega-dose 10-Grams-per-day quantities, divided throughout the day. Their results soon showed that Vitamin C helped with cancer, but not in convincing the medical establishment ― and a swirl of controversy like none he had experienced surrounded Linus Pauling.

The study, performed in Scotland, a country with an extremely high cancer rate reported that while 22% of cancer patients taking these huge doses of Vitamin C survived for more than a year after being labeled terminal ― only 0.4% of similar patients during that same time survived without the Vitamin. On average cancer patients taking the Vitamin C survived 4 times longer ― but in most cases this could be measured in days or months.

Pauling wanted the National Cancer Institute (NCI) to let him repeat the study in the US, but instead the NCI chose scientists at the Mayo Clinic. Results there under E.T. Creagan showed little going for the use of high dose Vitamin C in cancer.4 Pauling immediately objected on the grounds that most of the Mayo patients had received chemo and radiation, which weakened the very immune system needed for Vitamin C to be effective. This led to a repeat trial headed by Creagan’s second-in-command at Mayo, Charles Moertel, whose results led him again5 to denounce the use of megadose Vitamin C in advanced cancer ― even in patients with no prior chemotherapy.

This time Pauling and Cameron bounced back by saying that even this second study fell short as the vitamin was stopped prematurely if there were signs it wasn’t working. (Cameron and Pauling had continued Vitamin C indefinitely throughout their study). Also they criticized the Mayo study regarding the rebound effect that this could lead to and for not taking routine urine tests for Vitamin C prior to beginning the trial to make sure that control patients weren’t taking Vitamin C independent of the study. The controversy continued to swirl.

Actually Linus Pauling’s interest in Vitamin C grew from the research of biochemist Irwin Stone. Stone6 would eventually publish The Healing Factor: “Vitamin C” Against Disease. In the book Stone related that thru a mutation which occurred long ago man could not manufacture Vitamin C in his body.

This was a serious change, since organisms who can’t manufacture ascorbic acid (Vitamin C) were in danger of extinction. Stone placed this mutation as having occurred 55 to 65 million years ago.Ibid Scurvy, the disease resulting from too little Vitamin C could and would result.



Vitamin C

Stone’s popular book “The Healing Factor: Vitamin C Against Disease” – with a Forward from Linus Pauling, who Irwin Stone Inspired To Go On To do Vitamin C Research. Stone’s Cover Caption rightfully begins with: “Vitamin C may save your life!”



Daily Vitamin C – Necessary in Every Way


Stone captured that lack of Vitamin C could present as everything from a mild “not feeling right” to much, much more serious events called acute scurvy. The latter began with change of complexion (pale or muddy), loss of accustomed vigor, quick tiring, breathlessness and a desire for sleep, but progressed in severity to fleeting limb and joint pains, sore and bleeding gums, and small reddish spots (representing hemorrhaging), especially on leg hair follicles progressing at times to nosebleeds and blood in the urine. As the disease called scurvy advanced, teeth become loose and bones become so brittle that they could be broken by merely moving in bed. The body’s joints in the end became so damaged that the noise from the bones grinding upon on another could actually be heard as a rattling noise ― and death came by either sudden collapse on mild exertion or from secondary infection such as pneumonia.Ibid



Scurvy, a disease of significant Vitamin C deficiency becomes rapidly noticeable. Among its signs and symptoms are weakness, anemia, bruising, bleeding gums and loose teeth.

Scurvy, a disease of significant Vitamin C deficiency becomes rapidly noticeable. Among its signs and symptoms are weakness, anemia, bruising, bleeding gums and loose teeth.



For millennia, Stone said, man has suffered from lack of Vitamin C, and when the Hungarian Szent-Györgyi isolated it at Cambridge in 1928 and proved his findings in 1931, others were free to derive its chemical structure and produce it synthetically. Albert Szent-Györgyi came away with a Nobel Prize ― in research that began about as unexpectedly as Fleming’s find of penicillin.7




Chemical Formula of Vitamin C. Thanks to Szent-Gyorgyi, this Compound was Isolated and Could be Mass Produced.

Chemical Formula of Vitamin C. Thanks to Szent-Gyorgyi, this Compound was Isolated and Could be Mass Produced.



In The Healing Factor, Stone underscored that Vitamin C cannot adequately be stored. Therefore man needed to constantly replenish it through foods rich in Vitamin C. He felt the daily Vitamin C (ascorbic acid) recommended by the National Research Council of 60 mg. daily was woefully inadequate ― citing many scientists and doctors who agreed with him. Szent-Gyorgyi was among them, feeling that “the daily dosage of ascorbic acid should be much higher.”

By 1969, Stone had documented laboratory tests conducted at the National Cancer Institute which showed that ascorbic acid was lethal to certain cancer cells and harmless to normal tissue. This was all being carefully monitored by Dr. Virginia Livingston’s group at Rutgers’s ― which was at the time pulling in sizable grants from major corporations in her quest to prove that cancer was from a tubercular-like cancer germ, which stained acid-fast (as opposed to other microbes) and appeared routinely as the cause of cancer in both her laboratory animals and biopsied human tissue specimens.8

But after the discovery and isolation of Vitamin C in 1928, and the establishment of its underlying relationship to scurvy, the declining incidence of this disease has led to complacency, scurvy being thought of as a well-nigh extinct disease. All of this has resulted in failure to recognize and treat subclinical forms of this disease and its complicated relationship to other disease. Scurvy and its bleeding tendencies were caused by lack of Vitamin C of course. Why go further?



A Germ With “Particular Sensitivity” to Destruction Through Vitamin C


But actually the antiseptic and bacterial qualities of ascorbic acid have long been known and mycobacteria such as TB are heavily influenced by them. Moreover there began to appear laboratory proof that TB itself depleted Vitamin C levels badly and could in itself cause subclinical scurvy. According to Stone:
“The bacteria causing tuberculosis (Mycobacteria tuberculosis) is particularly sensitive to the lethal action of ascorbic acid”.Op.cit.

Two decades before its discovery and isolation, said Stone, ascorbic acid’s effect on mycobacteria such as tuberculosis began to seep into the literature empirically. As early as 1933, McConkey and Smith9 took guinea pigs fed tuberculous sputum daily and split them into two groups. The first group was subjected to a Vitamin C deficient diet, while the second group, fed two teaspoonfuls of Vitamin C rich tomato juice, completed the study. McConkey’s idea came from his clinical observation that patients hospitalized with the intestinal form of the tubercular disease, some of which were hemorrhaging, improved when tomato juice was added to their menu. In the Vitamin C deficient cohort group 26 of the animals died from intestinal ulcerations, while only 2 succumbed while taking tomato juice ― despite the small amounts (2mg) daily. This is what Stone meant when he said that TB was “particularly sensitive” to the lethal action of ascorbic acid.

McConkey’s work was confirmed by de Savitch10 ― with orange juice as the Vitamin’s source (deSavitsch et al.1934) and Birkhaug in 193811 ― both studies using what Stone felt were woefully inadequate amounts of C. Birkhaug was on to something quite important. Not only did Vitamin C protect against “the initial invasive onslaught of”Ibid progressive tubercular disease ― but the disease itself was depleting Vitamin C levels in the body.

Actually, such linkage of TB to scurvy, historically, was nothing new. No later than in 1689 did Richard Morton, one of the earliest writers on scurvy, mention in Phthisiologia, a book which gained him almost a century of fame, say:
“Scurvy is wont [accustomed] to occasion a consumption [tuberculosis] of the lungs.”12

Birkhagh though, was essentially saying that tubercular disease caused subclinical scurvy, mentioning:
“Our study has shown that by compensating for the inevitable state of hypovitaminosis [too little] C which occurs in progressive tuberculosis, we render the animal organism more resistant against the inflammatory-necrotizing effect of tuberculosis and the initial invasive onslaught of virulent tubercle bacilli.” (Birkhaug, 1938). But what Birkhaug was not picking up, according to Erwin Stone, was that that Vitamin C was drop-dead lethal to tuberculosis.

Like Birkhaugh, Andosca and Foley13 realized that tuberculosis itself created Vitamin C deficiency. Andosca: “Most authors maintain that there is a deficiency of vitamin C in tuberculous patients.” Faulkner and Taylor14, for example, disclosed an increased demand for Vitamin C with infection. Patients with tuberculosis required more than 200 mg. of ascorbic acid a day to keep the plasma level normal.

Subclinical Scurvy from TB

Bauer and Vorwerk15 found vitamin C deficiencies of from 1 to 4 grams in the tubercular, finding a direct parallel between the activity of tuberculosis and the extent of vitamin C deficiency. Borsalino16 reported a study of 140 tuberculosis patients, in which administration of vitamin C rapidly increased capillary resistance and stopped hemoptysis ― the spitting up of blood or blood-tinged sputum. However such blood loss reappeared when treatment was discontinued. By 1946, in a survey of nutrition among the northern Manitoba Indians, Moore et al17 reported a very high mortality rate from tuberculosis and pneumonia among these Canadian Indians ― which they attributed to a diet extremely low in Vitamin C.

As Irwin Stone pointed out, “There were many more reports in this sickening mass of continued repetition of ineffectual clinical tests where the investigators were correcting a nutritional deficiency instead of using ascorbic acid to actually combat the disease.”ibid In the meantime, the extent of Vitamin C deficiency or hypovitaminosis documented by Birkhaug with mycobacterial disease was soon realized to be equivalent in cancer, still another similarity in the two wasting diseases. (Carneron & Pauling, 1979)

Further positive animal studies that Vitamin C was a potent anti-tubercular were run separately by Kleimenhagen, Steinbach, and Boyden.18,19,20 culminating with Getz’s study21 of over 1000 men which intimated that were there were adequate Vitamin C blood levels ― there was no Mycobacteria tuberculosis. Still, persisted Stone: “The dogma of the vitamin theory kept these clinicians from thinking of ascorbic acid as an antibiotic and using it in the necessary antibiotic dosages.”ibid

That was until Charpy’s 1948 study22, in which a truly massive l5 Grams or 15,000 milligrams a day were given to terminal consumptive patients. These tubercular patients were so gone that one of them died before the study got underway, but the others survived and improved strikingly despite the fact that they seemed in Charpy’s words: “unaware of the enormous tuberculosis lesions they harbored”, a situation apparently again found analogous in studies of Vitamin C and cancer. Charpy does not go into possible toxicity of such high Vitamin C, nor the kidney stones that could result from it. Vitorero and Doyle23, on the other hand, found excellent results in the treatment of intestinal TB merely by injecting 500 to 600 milligrams of ascorbic acid a day initially, which was reduced to 400 milligrams as improvement was shown, and then further reduced to 200 milligrams a day. Vitorero and Doyle were quite positive about the benefits of this treatment in their few cases and recommended its use for intestinal tuberculosis.

Fast Forward to 2013

In her cancer diet, physician Virginia Livingston Op. cit used vitamins which included Vitamin C to combat her modified mycobacterial cancer germ, but not nearly to the extent of the high doses suggested by Pauling and others. But just how well Vitamin C, at the proper concentration killed even drug resistant TB had to wait until 2013.24

In an unexpected discovery, researchers at Albert Einstein College of Medicine determined that Vitamin C, all by itself, killed both TB and drug resistant TB on culture plates. The finding suggested that Vitamin C, added to existing TB drugs could enhance and possibly shorten TB therapy. The study was published in the online journal Nature Communications.

The molecular mechanism by which vitamin C exerted its lethal effect was that Vitamin C induced what is known as a Fenton reaction, causing iron to react with other molecules to create reactive oxygen species (ROS) that kill the TB (Mtb) mycobacteria.

Peculiar and Unique to TB above other microbes, Vitamin C -Through a Fenton reaction - Kills Tuberculosis (Mtb) by Causing Iron (Fe) to Create Reactive Oxygen Species (ROS) - Which Destroy Even Drug Resistant Strains of TB.

Peculiar and Unique to TB above other microbes, Vitamin C -Through a Fenton reaction – Kills Tuberculosis (Mtb) by Causing Iron (Fe) to Create Reactive Oxygen Species (ROS) – Which Destroy Even Drug Resistant Strains of TB.

What Irwin Stone had so long ago said and predicted ― that TB was “particularly sensitive” to Vitamin C ― was now recognized scientific reality.



1. Pauling, Linus. Vitamin C and the Common Cold. Bantam Books. New York. 1971.112pp.
2. Pauling, Linus. Vitamin C, the Common Cold, and the Flu. W.H. Freeman and Company. San Francisco. 1976.230pp
3. Pauling and Cameron, 1976). Pauling, Linus and Cameron, Ewan. Supplemental Ascorbate in the Supportive Treatment of Cancer. Proceedings of the National Academy of Sciences, Vol.73: pp.3685-89. 1976.
4. Creagan ET, Moertel CG et al.Failure of high-dose vitamin C (ascorbic a N Engl J Med1979 Sep 27;301(13):687-90) therapy to benefit patients with advanced cancer. A controlled trial.
5. Moertel CG, Fleming TR, Creagan ET, Rubin J, O’Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl. J Med. 1985 Jan 17; 312(3):137-41)
6. Stone, Irwin. The Healing Factor- “Vitamin C” Against Disease. Grosset & Dunlap Publishers. New York. 1972.)
7. Kyle, R. A.; Shampo, M. A. (2000). “Albert Szent-Györgyi–Nobel laureate”. Mayo Clinic proceedings. Mayo Clinic 75 (7): 722
8. Livingston-Wheeler V, Addeo EG. The conquest of cancer. CreateSpace Independent Publishing Platform. January 30, 2013. Pp. 288.
9. McConkey, M. and D.T. Smith. The Relation of Vitamin C Deficiency to Intestinal Tuberculosis in the Guinea Pig. Journal of Experimental Medicine. Vol.58: pp. 503-12. 1933.
10. De Savitsch, et al. The Influence of Orange Juice on Experimental Tuberculosis in Guinea Pigs. National Tuberculosis Association Transactions. Vol. 30 pp. 130-135. 1934.
11. Birkhaug, K.E.. The Role of Vitamin C in the Pathogenesis of Tuberculosis in the Guinea Pig. I to V. Acta Tubeculosis Scandinavica, Vol 12: pp. 89-98, 98-104, 359-372. 1938.
12. Morton, R. Phthisiologia, seu, Exercitationes de phthisi tribus libris comprehensae totumque opus variis historiis illustratum . Latin Edition. EEBO Editions, ProQuest Publishers. (Latin) Paperback – January 3, 2011. 444pp 1689.
13. Andosca JB, Foley JA. Calcium Ribonate and Vitamin C (Nu 240-10) in the Treatment of Tuberculosis Chest.1948;14(1):107-114. p.109.
14. Faulkner J, Taylor F. Vitamin C and Infection: Ann. Int. Med.. 10:1867. 1931.
15. (Baur and Vorwerk. “Beitrag sum Vitamin C Deficit bei Lungentuberculosen.” Beitr. S. Tuberk., 91: 262, 1938)
16. Borsalino, G. “Fragilite Capillare nella Tuberculose Polmonare e le sue Modificazione par azione della vitamin C.” Gior. de clin. Med., 18: 273, 1931.
17. Moore, et al. “Nutrition among Northern Manitoba Indians.” Can. Med. Assoc. J., 54: 223, 1946.
18. Kleimenhagen, P.. Effect of Ascorbic Acid on Experimental Tuberculosis in Guinea Pigs. Zeitschrift fur Vitaminforschung. Vol 11: 209-227. 1941.
19. Steinbach, M. M. and Klein, S.J. Vitamin C in Experimental Tuberculosis in Guinea Pigs. American Review of Tuberculosis. Vol 43: 403-13. 1941.
20. (Boyden, SV, Anderson, ME. Diet and Experimental Tuberculosis in the Guinea Pig. Acta Pathologica et Microbiologica Scandinavia (Kobenhavn). Vol. 39: 107-16. 1956.
21. Getz, 1951). (Getz, HA, Henderson HJ. A Study of the Relation of Nutrition to the Development of Tuberculosis; influence of ascorbic acid and vitamin A. Am Rev Tuberc. 1951 Oct; 64(4):381–393.
22. Charpy, J., and Ascorbic Acid in Very Large Doses Alone or with Vitamin D in Tuberculosis. Bulletin de I’Academie Nationale de Medicine (Paris). Vol. 83:421-3. 1948.
23. Vitorero, JRB, Doyle, J. Treatment of intestinal tuberculosis with vitamin C, Med. Wkly., 2, 636, 1938
24. Vilchèze C, Hartman T, Weinrick B, Jacobs WR Jr. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat Commun. 2013, May;4:1881. 23 pp.

© U.S. Library of Congress
All rights reserved
November 1, 2014

SEE also: